Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21796357 | 1.00 | EPHX2 (0.32) | EPHX2NR1H4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17891797 | 0.87 | EPHX1 (0.34) | EPHX2NR1H4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17831661 | 0.77 | CYP2D6 (0.42) | EPHX2NR1H4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30665778 | 0.77 | CYP2D6 (0.42) | EPHX2NR1H4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17891912 | 0.77 | EPHX2 (0.36) | EPHX2NR1H4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17891836 | 0.71 | EPHX2 (0.33) | EPHX2NR1H4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17891798 | 0.71 | EPHX2 (0.33) | EPHX2NR1H4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17891835 | 0.71 | EPHX2 (0.33) | EPHX2NR1H4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19480918 | 0.69 | S1PR1 (0.31) | — | |
| SCHEMBL9917316 | 0.69 | IDO1 (0.50) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| EP-3744713-A1 | DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | Japan Tobacco Inc. (JP) | 2020-12-02 | — | — | EP | disclosed |
| EP-3231793-B1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC (JP) | 2020-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | EPHX2 3024/4885NR1H4 812/4885CYP2D6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.